Determination of Regulatory Review Period for Purposes of Patent Extension; Wallstent Coronary Endoprosthesis

Summary

The Food and Drug Administration (FDA) has determined the regulatory review period for the Wallstent Coronary Endoprosthesis, a medical device, and is publishing this notice as required by law. The FDA made this determination due to a patent extension application submitted to the Commissioner of Patents and Trademarks, Department of Commerce.